Selank (N-Acetyl Amidate) 10mg

What is N-Acetyl Selank?

N-Acetyl Selank (NAS) is a synthetic heptapeptide and a modified derivative of Selank, originally developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. Its sequence is Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro, with a molecular weight of approximately 793.9 g/mol. NAS enhances the original Selank structure (Thr-Lys-Pro-Arg-Pro-Gly-Pro) by adding an N-terminal acetyl group, which improves stability, lipophilicity, and blood-brain barrier penetration. It is a water-soluble peptide designed to target the central nervous system (CNS) with potentially greater potency and duration compared to Selank.

Mechanism of Action

N-Acetyl Selank’s primary mechanism involves amplifying Selank’s effects on anxiety reduction and cognitive enhancement, through the following processes:

GABA System Modulation: NAS indirectly enhances GABA receptor activity, increasing inhibitory neurotransmission to reduce anxiety, with improved CNS delivery due to acetylation, potentially offering stronger effects than Selank.

BDNF Upregulation: It increases brain-derived neurotrophic factor (BDNF) expression in the hippocampus, promoting neuroplasticity and memory, with greater potency attributed to its enhanced stability.

Enkephalin Stabilization: NAS inhibits enkephalin-degrading enzymes (e.g., carboxypeptidase), elevating endogenous opioid levels, contributing to anxiolytic and mood effects, possibly with prolonged action.

Monoamine Regulation: It modulates serotonin, dopamine, and norepinephrine turnover in the brain (e.g., hypothalamus, cortex), enhancing mood and cognition, with acetylation likely extending its half-life.

Anti-Stress Effects: NAS reduces cortisol and ACTH release by normalizing hypothalamic-pituitary-adrenal (HPA) axis activity, with improved efficacy due to better bioavailability.

Immune Modulation: It may upregulate IL-6 and balance T-helper cell responses, enhancing immunity under stress, with effects potentially amplified by its chemical modifications.

NAS’s enhanced stability and CNS penetration build on Selank’s profile, offering a more robust anxiolytic and nootropic candidate.

Benefits of N-Acetyl Selank

N-Acetyl Selank’s benefits, inferred from Selank studies and anecdotal reports, include:

Anxiety Reduction: Rapidly alleviates anxiety with potentially greater potency than Selank, without sedation or dependence.

Cognitive Enhancement: Improves memory, attention, and learning capacity, with users reporting stronger effects due to increased stability.

Stress Resilience: Protects against stress-induced physiological and behavioral damage more effectively, enhancing emotional stability.

Mood Improvement: Elevates mood and reduces depressive-like symptoms, with prolonged action compared to Selank.

Neuroprotection: Supports neuronal survival and plasticity, potentially offering enhanced recovery from stress or injury.

Immune Support: Bolsters immune responses under stress, with possible improvements over Selank due to better pharmacokinetics.

These benefits suggest NAS as a superior alternative to Selank for mental health and cognitive applications.

Use Cases of N-Acetyl Selank

N-Acetyl Selank is primarily experimental and used off-label, with applications including:

Anxiety Disorders: Used for generalized anxiety or stress-related anxiety (e.g., 200-750 mcg/day intranasal) in research and anecdotal settings.

Cognitive Enhancement: Applied by healthy individuals or students (e.g., 300-600 mcg/day intranasal) for memory and focus improvement.

Stress Management: Investigated to mitigate chronic stress or burnout (e.g., 100-500 mcg/day SC or intranasal) in preclinical and off-label use.

Mood Disorders: Explored for mild depression or emotional instability (e.g., 400 mcg/day) based on monoamine effects.

Neurological Conditions: Studied for potential in traumatic brain injury or cognitive decline (e.g., 5-10 mg/kg in rats) to support neuronal health.

Administration typically involves intranasal sprays or subcutaneous injections, with dosing tailored to research or user goals.

Research Studies

Below is a summary of key studies related to Selank (as direct NAS studies are scarce), with NAS effects inferred from modifications and anecdotal evidence:

Seredenin et al. (1998) – Bulletin of Experimental Biology and Medicine Showed Selank (0.1-1 mg/kg) reduces anxiety in rats via GABA modulation; NAS’s acetylation may enhance this effect.

Kozlovskaya et al. (2003) – Neuroscience and Behavioral Physiology Reported Selank (300 mcg/day intranasal) improves memory in stressed rats; NAS users claim stronger effects due to stability.

Semenova et al. (2010) – Bulletin of Experimental Biology and Medicine Found Selank (0.3 mg/kg) stabilizes enkephalins and reduces stress in rats; NAS may prolong this via better CNS delivery.

Zozulya et al. (2008) – Bulletin of Experimental Biology and Medicine Demonstrated Selank (200-450 mcg/day intranasal) reduces anxiety in GAD patients (n=62); NAS is anecdotally reported as more potent.

Uchakina et al. (2008) – Journal of Molecular Neuroscience Indicated Selank upregulates IL-6 in stressed mice; NAS’s improved pharmacokinetics may amplify this.

Kolomin et al. (2014) – Advances in Experimental Medicine and Biology Showed Selank (0.15 mg/kg) enhances serotonin turnover; NAS’s longer half-life may extend mood benefits.

No large-scale NAS-specific studies exist; its profile builds on Selank research with enhancements attributed to acetylation.

Considerations

Safety: Appears well-tolerated based on Selank data and user reports, with mild side effects (e.g., nasal irritation); long-term safety of NAS is unstudied.

Regulation: Not FDA-approved; available as a research chemical or via compounding pharmacies, with no clinical status.

Evidence: Inherits Selank’s preclinical and clinical support; NAS-specific data are anecdotal, lacking formal trials for validation.

In conclusion:

N-Acetyl Selank is a modified peptide with enhanced potential to reduce anxiety, boost cognition, and improve stress resilience by amplifying Selank’s mechanisms through improved stability and CNS penetration. While promising based on Selank’s foundation and user experiences, its lack of direct research necessitates further study to confirm its therapeutic role.

Legal Disclaimer
The information provided in this article is for research purposes only. Selank is not approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority for human consumption or therapeutic use. It is intended solely for investigational use in controlled laboratory settings by qualified researchers. Protide Health does not endorse or promote the use of Selank in humans or animals outside of approved research protocols. Researchers must comply with all applicable local, state, and federal regulations, including obtaining necessary approvals for experimental use. Consult with regulatory authorities before initiating any research involving Selank.